Evidence map›Paper›PMID 30600675›Full record

ArticleGut and liver2019

Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma.

Bo Hyun Kim, Joong-Won Park, Jin Sook Kim, Sook-Kyung Lee, Eun Kyung Hong

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut and liver, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. The role of CD133 in hepatocellular carcinoma.Cancer biology & therapy · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bo Hyun KimCenter for Liver Cancer,Division of Clinical Research, Research Institute, National Cancer Center, Goyang, Korea.
Joong-Won ParkCenter for Liver Cancer,Division of Clinical Research, Research Institute, National Cancer Center, Goyang, Korea.
Jin Sook KimCommon Cancer Branch, Division of Clinical Research, Research Institute, National Cancer Center, Goyang, Korea.
Sook-Kyung LeeCommon Cancer Branch, Division of Clinical Research, Research Institute, National Cancer Center, Goyang, Korea.
Eun Kyung HongCenter for Liver Cancer,Division of Clinical Research, Research Institute, National Cancer Center, Goyang, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aims: Sorafenib remains the only approved molecular targeted agent for hepatocellular carcinoma (HCC); however, reliable biomarkers that predict its efficacy are still lacking. The aim of this study was to explore whether cancer stem cell (CSC) markers have a predictive role with regard to the sorafenib response in HCC patients. Methods: We enrolled 47 patients with HCC for whom tumor samples obtained before starting sorafenib treatment were available. RNA was extracted from formalin-fixed, paraffin-embedded samples, and real-time polymerase chain reaction was used to quantify mRNA expression of the CSC genes Results: Of 47 patients, 14.9% and 74.5% had vascular invasion and extrahepatic spread, respectively. Patients with low Conclusions: Overexpression of the CSC markers

Indexed as

AdultAgedAntineoplastic AgentsBiomarkers, TumorCarcinoma, HepatocellularFemaleHumansLiver NeoplasmsMaleMiddle AgedNeoplastic Stem CellsPharmacogenomic TestingRNA, MessengerSorafenibTreatment OutcomeAntineoplastic AgentsBiomarkers, TumorRNA, MessengerSorafenibBiomarkersCancer stem cellsCarcinomahepatocellularPrognosisSorafenib

Identifiers

PMID30600675
PMCPMC6529171

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.